Clinical Trial Update: AXP107-11 in Combination With Standard Gemcitabine (Gemzar® ) Therapy for Treatment in Patients With Pancreatic Cancer [Phase 1, Phase 2]

View source ↗

Summary

Early-phase clinical trial evaluating AXP107-11 in combination with Gemcitabine (Gemzar) for pancreatic cancer, spanning Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• AXP107-11
• Gemzar (gemcitabine)

Snippet

Sponsor: Axcentua Pharmaceuticals AB | Conditions: Adenocarcinoma | Phase 1, Phase 2 | Status: UNKNOWN